Skip to content

Ketamine research published in 2024

Page 20 of 26: studies 381 to 400 of 518, newest first. Back to the ketamine overview

Studies

Ketamine Infusion in a Resistant Obsessive-Compulsive Disorder Patient in Bangladesh with Severe Suicidal Ideation: A Case Report.

Cureus April 1, 2024 Sultana Algin, Debasish Banik, Sm Atikur Rahman et al. 1 citation

Treatment of resistant obsessive-compulsive disorder (OCD) typically results in insufficient symptom alleviation, and even long-term medication often fails to have the intended effect. Ketamine is a potent non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor. Studies have shown that low-dose ketamine infusion results in a considerable reduction in obsessive-compulsive symptoms...

Potentiation of antidepressant effects: NPY1R agonist and ketamine synergy enhances TrkB signaling and neurogenesis in the ventral hippocampus.

Expert Opinion on Therapeutic Targets April 1, 2024 Carlos Arrabal-Gómez, Pedro Serrano-Castro, Jose Andrés Sánchez-Pérez et al. 7 citations

Major Depressive Disorder (MDD) poses a significant challenge to global health, with current treatments often limited by efficacy and onset delays. This study explores the synergistic antidepressant-like effects of an NPY1R agonist and Ketamine, targeting their neurobiological interactions within the ventral hippocampus. Utilizing a preclinical model, this study administered Neuropeptide Y...

DOI: 10.1080/14728222.2024.2342524 (opens in new tab) Full text (opens in new tab) Neurogenesis Antidepressant therapy Npy1r agonist Ventral hippocampus +9

Very Low-Dose Sublingual Ketamine for Borderline Personality Disorder and Treatment-Resistant Depression.

Cureus April 1, 2024 Mitchell B. Liester, Rachel Wilkenson, Barry Patterson et al. 3 citations

Borderline personality disorder (BPD) and treatment-resistant depression (TRD) are common mental disorders that are challenging to treat. Ketamine is an N-methyl-D-aspartate receptor antagonist that has shown promise as a rapid-acting antidepressant when administered intravenously. BPD symptoms have also been demonstrated to improve with repeated intravenous administration of ketamine, and a...

DOI: 10.7759/cureus.57654 (opens in new tab) Full text (opens in new tab) Ampa receptor Brain-derived neurotrophic factor Glutamate dysregulation Low dose ketamine +6

From Wheelchair Bound to Working: A Case Study of Intravenous Ketamine Infusions in Treating Stiff Person Syndrome.

Cureus April 1, 2024 Ashraf F Hanna, Danielle Bolling, Mariam Tadros 3 citations

Stiff Person Syndrome (SPS) is a rare autoimmune condition marked by extremely painful muscle spasms, stiffness, and rigidity throughout the body. Its rarity often translates to limited treatment options for patients and, occasionally, challenges in obtaining a definitive diagnosis. SPS also impacts patients' mental health, social and economic involvement, and overall quality of life. A...

DOI: 10.7759/cureus.59397 (opens in new tab) Full text (opens in new tab) Chronic pain Intravenous ketamine Ketamine hydrochloride Pain management +5

A comparison between psilocybin and esketamine in treatment-resistant depression using number needed to treat (NNT): A systematic review.

Journal of Affective Disorders April 1, 2024 Sabrina Wong, Angela T H Kwan, Kayla M Teopiz et al. 19 citations

Inadequate outcomes with monoamine-based treatments in depressive disorders are common and provide the impetus for mechanistically-novel treatments. Esketamine is a proven treatment recently approved for adults with Treatment-Resistant Depression (TRD) while psilocybin is an investigational treatment. Translation of the clinical meaningfulness for these foregoing agents in adults with TRD is...

Effects of New Psychoactive Substance Esketamine on Behaviors and Transcription of Genes in Dopamine and GABA Pathways in Zebrafish Larvae.

Bulletin of environmental contamination and toxicology March 31, 2024 Si-Ying Li, Wen-Jun Shi, Dong-Dong Ma et al. 9 citations

Esketamine (ESK) is the S-enantiomer of ketamine racemate (a new psychoactive substance) that can result in illusions, and alter hearing, vision, and proprioception in human and mouse. Up to now, the neurotoxicity caused by ESK at environmental level in fish is still unclear. This work studied the effects of ESK on behaviors and transcriptions of genes in dopamine and GABA pathways in zebrafish...

Ketamine and epigenetic processes in depression, intersection between serotonergic and glutamatergic pathways

Journal of Psychedelic Studies March 29, 2024 Arghavan Nepton, Hesam Farahani, Monnica T. Williams et al. 2 citations

Abstract Background Hypotheses surrounding the etiology of depressive disorders encompass a wide range of biological changes that can occur in a depressed individual, from gene variations to epigenetic modifications and not only serotonergic mechanisms. Once again, the therapy response of the patient to antidepressants is connected to modifications in the epigenetic regulation of genes within...

Comparative brain-wide mapping of ketamine- and isoflurane-activated nuclei and functional networks in the mouse brain.

Elife March 21, 2024 Yue Hu, Wenjie Du, Jiangtao Qi et al. 27 citations

Ketamine (KET) and isoflurane (ISO) are two widely used general anesthetics, yet their distinct and shared neurophysiological mechanisms remain elusive. In this study, we conducted a comparative analysis of the effects of KET and ISO on c-Fos expression across the mouse brain, utilizing hierarchical clustering and c-Fos-based functional network analysis to evaluate the responses of individual...

High-order brain interactions in ketamine during rest and task: A double-blinded cross-over design using portable EEG.

Research Square March 21, 2024 Agustin Ibanez, Rubén Herzog, Florentine Barbey et al. 1 citation preprint

In a double-blinded cross-over design, 30 adults (mean age = 25.57, SD = 3.74; all male) were administered racemic ketamine and compared against saline infusion as a control. Both task-driven (auditory oddball paradigm) and resting-state EEG were recorded. HOI were computed using advanced multivariate information theory tools, allowing us to quantify nonlinear statistical dependencies between...

DOI: 10.21203/rs.3.rs-3954073/v1 (opens in new tab) Full text (opens in new tab) Psychopharmacology Consciousness-research Brain-connectivity Ketamine-studies

Effect of Acute Ketamine Treatment on Sympathetic Regulation Indexed by Electrodermal Activity in Adolescent Major Depression.

Pharmaceuticals March 10, 2024 Veronika Kovacova, Andrea Macejova, Ingrid Tonhajzerova et al. 4 citations

Ketamine is a potential rapid-onset antidepressant characterized by sympathomimetic effects. However, the question of ketamine's use in treating adolescents' major depressive disorder (MDD) is still discussed. Thus, we aimed to study the acute effect of ketamine infusion treatment on sympathetic regulation using electrodermal activity (EDA) in addition to an assessment of depressive...

DOI: 10.3390/ph17030358 (opens in new tab) Full text (opens in new tab) Major depressive disorder Adolescence Depressive symptomatology Electrodermal activity +12

Fabrication of a Controlled-Release Core-Shell Floating Tablet of Ketamine Hydrochloride Using a 3D Printing Technique for Management of Refractory Depressions and Chronic Pain.

Polymers March 8, 2024 Tahmineh Karami, Emad Ghobadi, Mohammad Akrami et al. 13 citations

In this study, a novel floating, controlled-release and core-shell oral tablet of ketamine hydrochloride (HCl) was produced using a dual extrusion by 3D printing method. A mixture of Soluplus® and Eudragit® RS-PO was extruded by a hot-melt extrusion (HME) nozzle at 150-160 °C to fabricate the tablet shell, while a second nozzle known as a pressure-assisted syringe (PAS) extruded the etamine HCl...

DOI: 10.3390/polym16060746 (opens in new tab) Full text (opens in new tab) Ketamine 3d printing Additive manufacturing Extended release +7

Perioperative Adjunctive Esketamine for Postpartum Depression Among Women Undergoing Elective Cesarean Delivery

JAMA Network Open March 6, 2024 Yu Chen, Yu Guo, Han Wu et al. 63 citations

Importance Postpartum depression (PPD) is one of the most common mental health conditions during the perinatal and postpartum periods, which can have adverse effects on both mother and infant. Objective To investigate the efficacy of perioperative adjunctive esketamine administration after cesarean deliveries in the prevention of PPD. Design, Setting, and Participants A single-center,...

DOI: 10.1001/jamanetworkopen.2024.0953 (opens in new tab) Full text (opens in new tab) Postpartum-depression Cesarean-section Mental-health Maternal-health +1

Opioid receptor expressing neurons of the central amygdala gate behavioral effects of ketamine in mice.

bioRxiv : the preprint server for biology March 6, 2024 Matthew B Pomrenze, Sam Vaillancourt, Pierre Llorach et al. 1 citation preprint

Ketamine has anesthetic, analgesic, and antidepressant properties which may involve multiple neuromodulatory systems. In humans, the opioid receptor (OR) antagonist naltrexone blocks the antidepressant effect of ketamine. It is unclear whether naltrexone blocks a direct effect of ketamine at ORs, or whether normal functioning of the OR system is required to realize the full antidepressant...

A Phase 2 Open Label Study of Efficacy, Safety, and Tolerability of SLS-002 (Intranasal Racemic Ketamine) in Adults with MDD at Imminent Risk of Suicide.

Psychopharmacology Bulletin March 4, 2024 Timothy Whitaker, Kimberly F Farrand, Michael E. Thase 249 citations

Despite the prevalence of Major Depressive Disorder (MDD) and the propensity of affected individuals to eventually die by suicide, there is no therapeutic approved specifically for suicidal ideation and behavior (SI/B) in MDD. The NMDA receptor antagonist ketamine has been investigated for the treatment of depression and shown to have a rapid effect on symptoms. Spravato® (esketamine) is...

Features of biliary tract diseases in ketamine abusers: a systematic review of case reports.

Journal of Medical Case Reports March 3, 2024 Alireza Teymouri, Hadis Nasoori, Maryamsadat Fakheri et al. 20 citations

Anesthesiologists prefer ketamine for certain surgeries due to its effectiveness as a non-competitive inhibitor of the N-methyl-D-aspartate receptor in the brain. Recently, this agent has also shown promise as an antidepressant. However, ketamine can cause hallucinogenic effects and is sometimes abused as an illicit drug. Ketamine abuse has been associated with liver and bile duct...

Depression-like phenotypes in mice following common bile duct ligation: Insights into the gut-liver-brain axis via the vagus nerve.

Neurobiology of Disease March 1, 2024 Yong Yang, Akifumi Eguchi, Chisato Mori et al.

Depression frequently occurs in patients with liver cirrhosis, yet the reasons for this correlation are not fully understood. Dysbiosis of gut microbiota has been implicated in depression through the gut-brain axis via the vagus nerve. This study explored the potential role of the gut-liver-brain axis via the vagus nerve in depression-like phenotypes in mice with liver cirrhosis. These mice...

Changes in information integration and brain networks during propofol-, dexmedetomidine-, and ketamine-induced unresponsiveness.

British Journal of Anaesthesia March 1, 2024 Zhenhu Liang, Yu Chang, Xiaoge Liu et al. 10 citations

Information integration and network science are important theories for quantifying consciousness. However, whether these theories propose drug- or conscious state-related changes in EEG during anaesthesia-induced unresponsiveness remains unknown. A total of 72 participants were randomised to receive i.v. infusion of propofol, dexmedetomidine, or ketamine at a constant infusion rate until loss...

DOI: 10.1016/j.bja.2023.11.033 (opens in new tab) Full text (opens in new tab) Ketamine Brain network Dexmedetomidine Electroencephalography +1

Loss of the sustained antidepressant-like effect of (2R,6R)-hydroxynorketamine in NMDA receptor GluN2D subunit knockout mice.

Journal of Pharmacological Sciences March 1, 2024 Aimi Yamagishi, Yuiko Ikekubo, Masayoshi Mishina et al. 6 citations

Ketamine, an N-methyl-d-aspartate (NMDA) receptor antagonist, has attracted attention for its acute and sustained antidepressant effects in patients with depression. Hydroxynorketamine (HNK), a metabolite of ketamine, exerts antidepressant effects without exerting ketamine's side effects and has attracted much attention in recent years. However, the detailed pharmacological mechanism of action...

DOI: 10.1016/j.jphs.2024.01.008 (opens in new tab) Full text (opens in new tab) Glun2d Hydroxynorketamine Tail-suspension test Depression treatment +3

Formulary Coverage of Esketamine and Ketamine for Depression in Ohio Health Insurance Marketplace and Medicaid Plans.

Journal of Psychiatric Practice March 1, 2024 Brian S. Barnett 5 citations

For more than 2 decades, intravenous ketamine has been demonstrated to have rapid antidepressant effects. However, access to this generic drug is limited due to insurers claiming it is "experimental" because ketamine does not have a Food and Drug Administration indication for depression. In contrast, intranasal esketamine, an enantiomer of ketamine, is approved by the Food and Drug...

DOI: 10.1097/PRA.0000000000000766 (opens in new tab) Full text (opens in new tab) Ketamine therapy Mental health insurance Depression treatment Healthcare coverage +1

How the Food and Drug Administration Drug Approval Process Relates to the Potential Approval of Intravenous Racemic Ketamine for Treatment-resistant Major Depression.

Journal of Psychiatric Practice March 1, 2024 Sheldon H. Preskorn

This column focuses on the status of intravenous racemic ketamine for the treatment of patients suffering from a form of major depressive disorder that does not respond to trials of currently available biogenic amine antidepressants. To provide context, the column reviews the 3 pivotal elements of the usual Food and Drug Administration (FDA) drug approval process: (1) the unmet medical need...

DOI: 10.1097/PRA.0000000000000768 (opens in new tab) Full text (opens in new tab) Ketamine therapy Depression treatment FDA Drug Approval Psychiatric medicine +1